Protocols - Page 5 of 6 - PeptideDosing.ca

19 Feb

Ipamorelin (10 mg Vial) — Evidence profile

A controlled postoperative study answers a narrow clinical question. It does not establish a broad recovery or body-composition use. This profile distinguishes the labelled product, study findings and evidence limits.

19 Feb

Single Peptides

HCG (5000 IU vial) — Evidence profile

Human chorionic gonadotropin is a hormone whose interpretation depends on the clinical indication and the exact product. This profile distinguishes the labelled product, study findings and evidence limits.

13 Feb

Single Peptides

Epithalon (10 mg Vial) — Evidence profile

Epitalon research includes telomere biology and neuroendocrine experiments. These findings need careful separation from claims about human lifespan. This profile distinguishes the labelled product, study findings and evidence limits.

13 Feb

Single Peptides

DSIP (10 mg Vial) — Evidence profile

Delta sleep-inducing peptide has been investigated in experimental sleep research. The reviewed human study is too small to establish a routine insomnia treatment. This profile distinguishes the labelled product, study findings and evidence limits.

13 Feb

Single Peptides

Crystagen (20 mg Vial) — Evidence profile

The reviewed Crystagen report describes immune-tissue measurements and includes a result showing no change in cellular renewal. This profile distinguishes the labelled product, study findings and evidence limits.

12 Feb

Single Peptides

Cartalax (20 mg Vial) — Evidence profile

Cartalax is associated with the short sequence AED. The selected primary work examines cellular aging markers rather than clinical joint outcomes. This profile distinguishes the labelled product, study findings and evidence limits.

12 Feb

Single Peptides

Cardiogen (20 mg Vial) — Evidence profile

The selected Cardiogen source examines cell biology. Its name does not establish a treatment for cardiovascular disease. This profile distinguishes the labelled product, study findings and evidence limits.

12 Feb

Single Peptides

Cagrilintide (10 mg Vial) — Evidence profile

Cagrilintide is a long-acting amylin analogue studied for weight management. Evidence for the individual molecule should be separated from combination research. This profile distinguishes the labelled product, study findings and evidence limits.

06 Feb

Single Peptides

Selank (10 mg Vial) — Evidence profile

The selected clinical report concerns anxiety-related conditions. Its findings should be read with the small evidence base and incomplete method details in mind. This profile distinguishes the labelled product, study findings and evidence limits.

06 Feb

Single Peptides

Semax (10 mg Vial) — Evidence profile

The selected Semax report concerns acute stroke care, a setting that differs substantially from cognitive enhancement in healthy people. This profile distinguishes the labelled product, study findings and evidence limits.